Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586867 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL13145206 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL14681105 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL21116108 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL23640225 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL14093611 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL23478046 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL11946936 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL23478009 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 | |
| SCHEMBL21946656 | 1.00 | FUCA1 (0.38) | FUCA1CA9CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371162-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8853385-B2 | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8058245-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110059912-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-10 | — | — | US | disclosed |
| US-7732596-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| US-20070197449-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371162-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | DPP4, SLC5A1, GLP1R | FUCA1 3243/4885CA9 492/4885CA12 2023/4885 |
| US-20110059912-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | DPP4, SLC5A1, GLP1R | FUCA1 3243/4885CA9 492/4885CA12 2023/4885 |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | FUCA1 1549/4885CA9 1683/4885CA12 4039/4885 |
| US-20070197449-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | FUCA1 1226/4885CA9 1567/4885CA12 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.